Davide Melisi
Impact in
- Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 1%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 88
- Pancreatic and Hepatic Oncology Research 64
- Colorectal Cancer Treatments and Studies 13
-
- Cancer Genomics and Diagnostics 22
- NF-κB Signaling Pathways 8
- Co-authors
- Giampaolo Tortora (41 shared papers)Carmine Carbone (25 shared papers)Paul J. Chiao (10 shared papers)Fortunato Ciardiello (13 shared papers)Antoine Hollebecque (8 shared papers)Hui‐Ling Zhen (7 shared papers)Geny Piro (20 shared papers)Luis Roberto Féliz (6 shared papers)
- Journals
- Annals of Oncology (25 papers)Clinical Cancer Research (11 papers)European Journal of Cancer (8 papers)ESMO Open (6 papers)Future Oncology (5 papers)
- Partner nations
- ItalyUnited StatesFrance
In The Last Decade
Davide Melisi
152 papers receiving 7.8k citations
Davide Melisi's Hit Papers
Peers
Comparison fields: 5 of 111
- Oncology 3.5k
- Cancer Research 1.4k
- Hepatology 462
- Surgery 1.8k
- Pulmonary and Respiratory Medicine 1.3k
Countries citing papers authored by Davide Melisi
This map shows the geographic impact of Davide Melisi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Davide Melisi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Davide Melisi more than expected).
Fields of papers citing papers by Davide Melisi
This network shows the impact of papers produced by Davide Melisi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Davide Melisi. The network helps show where Davide Melisi may publish in the future.
Co-authors
The 25 scholars most cited alongside Davide Melisi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 163 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study Hit paper breakdown → | 2020 | 1207 |
| 2 | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study Hit paper breakdown → | 2023 | 514 |
| 3 | 2004 | 309 | |
| 4 | NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2023 | 293 |
| 5 | 2008 | 284 | |
| 6 | 2018 | 257 | |
| 7 | Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib Hit paper breakdown → | 2020 | 232 |
| 8 | 2014 | 180 | |
| 9 | 2018 | 174 | |
| 10 | 2021 | 172 | |
| 11 | 2020 | 142 | |
| 12 | Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. | 2003 | 135 |
| 13 | 2011 | 135 | |
| 14 | 2016 | 130 | |
| 15 | 2017 | 127 | |
| 16 | 2008 | 124 | |
| 17 | 2019 | 114 | |
| 18 | 2006 | 113 | |
| 19 | 2015 | 102 | |
| 20 | 2007 | 90 |
About Davide Melisi
Davide Melisi is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Surgery and Molecular Biology, having authored 163 papers that have together received 7.9k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (64 papers), Cancer Genomics and Diagnostics (22 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (20 papers), Colorectal Cancer Treatments and Studies (13 papers), Gastric Cancer Management and Outcomes (13 papers), Fibroblast Growth Factor Research (11 papers), NF-κB Signaling Pathways (8 papers) and Lung Cancer Treatments and Mutations (8 papers). The work is most often cited by research in Oncology (3.5k citations), Cancer Research (1.4k citations), Hepatology (462 citations), Surgery (1.8k citations) and Pulmonary and Respiratory Medicine (1.3k citations). Davide Melisi has collaborated with scholars based in Italy, United States and France. Frequent co-authors include Giampaolo Tortora, Carmine Carbone, Paul J. Chiao, Fortunato Ciardiello, Antoine Hollebecque, Hui‐Ling Zhen, Geny Piro, Luis Roberto Féliz, Roberto Bianco and Camilla Zecchetto. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, European Journal of Cancer, ESMO Open and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.